Cover Image
市場調查報告書

三陰性乳癌 (TNBC) :流行病學、患者為基礎的市場預測,治療流程,及上市藥、開發平台藥物分析

Breast cancer: triple - negative: Epidemiology and patient-based market forecasts, treatment algorithm, and marketed and pipeline drug analysis

出版商 Datamonitor Healthcare 商品編碼 365189
出版日期 內容資訊 英文 290 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
三陰性乳癌 (TNBC) :流行病學、患者為基礎的市場預測,治療流程,及上市藥、開發平台藥物分析 Breast cancer: triple - negative: Epidemiology and patient-based market forecasts, treatment algorithm, and marketed and pipeline drug analysis
出版日期: 2016年05月01日 內容資訊: 英文 290 Pages
簡介

本報告以三陰性乳癌 (TNBC)的已上市及臨床實驗中 (開發平台上)的治療藥為焦點,提供在TNBC市場中有最大的商業可能性的預測首發藥,免疫療法帶給TNBC治療流程的影響,多ADP核糖聚合酵素 (PARB) 抑制劑的Lynparza,niraparib,talazoparib 及 veliparib的競爭,非專利、生技仿製藥治療藥投入市場的時期與對收益的影響等相關分析。

預測:三陰性乳癌 (TNBC)

  • 摘要整理
  • 市場概要、趨勢
  • 市場定義、調查手法
  • Abraxane (albumin-bound paclitaxel)
  • Atezolizumab
  • Avastin (bevacizumab)
  • glembatumumab vedotin
  • Halaven (eribulin mesylate)
  • Keytruda (pembrolizumab)
  • Lynparza (olaparib)
  • Niraparib
  • sacituzumab govitecan
  • Talazoparib
  • Veliparib
  • 1次調查手法

治療:三陰性乳癌 (TNBC)

  • 摘要整理
  • 疾病定義、診斷
  • 1次調查手法
  • 患者區分
  • 各國治療系統
  • 目前治療選擇
  • 處方趨勢
  • 未滿足需求

流行病學:三陰性乳癌 (TNBC)

  • 摘要整理
  • 疾病的背景
  • 來源、手法
  • 預測
  • 流行病學者的見解
  • 優勢和弱點

上市藥:三陰性乳癌 (TNBC)

  • 摘要整理
  • 產品概要
  • 產品簡介:Abraxane
  • 產品簡介:Avastin
  • 產品簡介:Halaven

開發平台:三陰性乳癌 (TNBC)

  • 摘要整理
  • 臨床實驗平台概要
  • 目標產品簡介
  • 產品簡介 (後期階段) :Keytruda
  • 產品簡介 (後期階段) :Lynparza
  • 產品簡介 (後期階段) :atezolizumab
  • 產品簡介 (後期階段) :glembatumumab vedotin
  • 產品簡介 (後期階段) :niraparib
  • 產品簡介 (後期階段) :sacituzumab govitecan
  • 產品簡介 (後期階段) :talazoparib
  • 產品簡介 (後期階段) :veliparib

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: DMKC11481

The aggressive nature of triple-negative breast cancer and a lack of targeted therapies creates opportunities for pipeline candidates to fulfil areas of high unmet need.

This report addresses the following questions:

  • Which branded therapies will have the largest commercial potential in the triple-negative breast cancer market?
  • What impact will immunotherapies have on treatment algorithms in triple-negative breast cancer?
  • How will competing poly (ADP-ribose)polymerase (PARP) inhibitors Lynparza, niraparib, talazoparib, and veliparib fare against one another?
  • How will pipeline therapies aim to address areas of unmet need?
  • When will generic and biosimilar therapies enter the market and what impact will they have on revenues?

TABLE OF CONTENTS

FORECAST: TRIPLE-NEGATIVE BREAST CANCER

  • 1. Executive Summary
  • 2. Market Overview and Trends
  • 3. Market Definition and Methodology
  • 4. Abraxane (albumin-bound paclitaxel)
  • 5. Atezolizumab
  • 6. Avastin (bevacizumab)
  • 7. glembatumumab vedotin
  • 8. Halaven (eribulin mesylate)
  • 9. Keytruda (pembrolizumab)
  • 10. Lynparza (olaparib)
  • 11. Niraparib
  • 12. sacituzumab govitecan
  • 13. Talazoparib
  • 14. Veliparib
  • 15. Primary Research Methodology

TREATMENT: TRIPLE-NEGATIVE BREAST CANCER

  • 16. Executive Summary
  • 17. Disease Definition and Diagnosis
  • 18. Primary Research Methodology
  • 19. Patient Segmentation
  • 20. Country Treatment Trees
  • 21. Current Treatment Options
  • 22. Prescribing Trends
  • 23. Unmet Needs in Triple-Negative Breast Cancer

EPIDEMIOLOGY: TRIPLE-NEGATIVE BREAST CANCER

  • 24. Executive Summary
  • 25. Disease Background
  • 26. Sources and Methodology
  • 27. Forecast
  • 28. Epidemiologist Insight
  • 29. Strengths and Limitations

MARKETED DRUGS: TRIPLE-NEGATIVE BREAST CANCER

  • 30. Executive Summary
  • 31. Product Overview
  • 32. Product profile: Abraxane
  • 33. Product profile: Avastin
  • 34. Product profile: Halaven

PIPELINE: TRIPLE-NEGATIVE BREAST CANCER

  • 35. Executive Summary
  • 36. Clinical Pipeline Overview
  • 37. Target Product Profile
  • 38. Product profile (late stage): Keytruda
  • 39. Product profile (late stage): Lynparza
  • 40. Product profile (late stage): atezolizumab
  • 41. Product profile (late stage): glembatumumab vedotin
  • 42. Product profile (late stage): niraparib
  • 43. Product profile (late stage): sacituzumab govitecan
  • 44. Product profile (late stage): talazoparib
  • 45. Product profile (late stage): veliparib
Back to Top